Vestmark Advisory Solutions Inc. Has $5.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)

Vestmark Advisory Solutions Inc. increased its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 12.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 137,367 shares of the biotechnology company's stock after acquiring an additional 14,791 shares during the quarter. Vestmark Advisory Solutions Inc. owned about 0.18% of Veracyte worth $5,440,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of VCYT. Jones Financial Companies Lllp boosted its holdings in Veracyte by 49.7% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 237 shares during the period. US Bancorp DE raised its position in shares of Veracyte by 57.4% during the fourth quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock valued at $70,000 after buying an additional 647 shares during the last quarter. Principal Securities Inc. lifted its stake in shares of Veracyte by 34.1% in the fourth quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock valued at $76,000 after buying an additional 485 shares during the period. KBC Group NV grew its position in Veracyte by 13.7% during the third quarter. KBC Group NV now owns 2,677 shares of the biotechnology company's stock worth $91,000 after buying an additional 323 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new position in Veracyte during the fourth quarter valued at about $91,000.

Insider Activity at Veracyte

In other Veracyte news, Director Karin Eastham sold 10,000 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $40.30, for a total transaction of $403,000.00. Following the sale, the director now owns 18,497 shares of the company's stock, valued at $745,429.10. This represents a 35.09 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.30% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of analysts have commented on the company. The Goldman Sachs Group reiterated a "neutral" rating and issued a $37.00 price objective (down previously from $38.00) on shares of Veracyte in a research report on Thursday, December 5th. Wolfe Research began coverage on shares of Veracyte in a research note on Friday, November 15th. They set an "outperform" rating and a $50.00 price target on the stock. Needham & Company LLC reissued a "buy" rating and issued a $51.00 price target on shares of Veracyte in a report on Tuesday, February 25th. Guggenheim reaffirmed a "buy" rating and set a $45.00 price objective on shares of Veracyte in a report on Tuesday, February 25th. Finally, StockNews.com lowered shares of Veracyte from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Veracyte currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

Veracyte Trading Down 5.1 %

Shares of Veracyte stock traded down $1.64 during mid-day trading on Monday, reaching $30.38. 1,389,583 shares of the stock were exchanged, compared to its average volume of 809,629. Veracyte, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $47.32. The company has a market cap of $2.37 billion, a price-to-earnings ratio of -202.53 and a beta of 1.80. The firm has a 50-day simple moving average of $40.61 and a 200 day simple moving average of $37.73.

Veracyte (NASDAQ:VCYT - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.07. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The company had revenue of $118.63 million during the quarter, compared to analyst estimates of $110.73 million. During the same quarter last year, the business posted ($0.39) earnings per share. On average, research analysts predict that Veracyte, Inc. will post 0.68 EPS for the current fiscal year.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.